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I
 
n this issue of 
 
The Journal of Experimental Medicine
 
, Tuohy
et al. study the spreading of the autoimmune response to
myelin antigens in experimental autoimmune encephalo-
myelitis (EAE) and its likely human counterpart, multiple
sclerosis (MS) (1). They demonstrate that as disease devel-
ops in EAE and MS, reactivity to the initiating antigen di-
minishes, and an orderly and definable set of new immune
reactivities arises. The data are clear and the scope of the
study in humans and in experimental animals is broad. For
example, the investigators elegantly look at T cells in the
central nervous system (CNS) in EAE to see whether the
reduction in peripheral activity is due to sequestration of
such T cells in the brain and spinal cord. The answer to this
question is a resounding “no.” Loss of reactivity is not due
to sequestration of the immune response in the CNS. The
implications of this study present challenges to the doctrine
of “original antigenic sin,” and to the hope of developing
antigen-specific therapy for autoimmune disease.
In organ-specific autoimmune diseases such as MS, rheu-
matoid arthritis, and insulin-dependent diabetes mellitus
(IDDM), there are vigorous debates among experts on which
antigen triggered the autoimmune response. Furthermore,
there are arguments about which antigens dominate the
diverse immune responses that can be detected at the site of
disease. Thus, in MS, where an apparent autoimmune T
and B cell response occurs in myelin sheath of the CNS,
there are arguments whether the initial or dominant im-
mune response might be directed at myelin basic protein
(MBP; references 2–4), myelin oligodendroglial glycopro-
tein (MOG; references 5, 6), proteolipid protein (PLP; ref-
erence 7), or various other myelin antigens (8). For IDDM,
investigators argue whether the primary response is against
glutamic acid decarboxylase (9, 10), insulin (11), heat shock
protein 65 (12), or other islet cell antigens.
The concept of epitope spreading described by Lehmann
et al. for EAE describes how antigen-specific autoimmune
responses can spread to different epitopes on one protein,
termed “intramolecular epitope spreading” (13), to other epi-
topes on other structural proteins, termed “intermolecular
epitope spreading” (14), at the site of disease (Fig. 1). Thus,
in EAE induced with an injection of an epitope of PLP, the
immune reactivity of populations or ensembles of T cells
can spread to other epitopes on PLP, and then on to other
myelin antigens such as MBP and MOG. Tuohy et al. dem-
onstrate that during the course of EAE initiated by immu-
nization to one epitope both intramolecular and intermo-
lecular epitope spreading allow the autoimmune response
to evolve in an orderly manner to encompass detectable T
cell responses to other epitopes on the initiating antigen
and to other myelin antigens. Remarkably the T cell re-
sponse to the initiating epitope is lost as disease progresses.
When Tuohy et al. searched for this phenomenon in hu-
man demyelinating disease, they faced a truly complicated
task. For it is difficult to know exactly when that disease is
initiated. In fact, some scientists argue that autoimmune dis-
eases, such as MS and IDDM, are due to a clinical deficit
that occurs only years after the primary event. Fortunately,
the investigators were able to follow, over the period of
many years, the response of peripheral blood lymphocytes
in patients with an isolated neurologic deficit as it evolved
into clinically definite MS. As patients progressed to MS,
they lost reactivity to the myelin epitopes that were recog-
nized during the initial immune response, and developed T
cell immune reactivity to other myelin epitopes. The hu-
man studies revealed smaller stimulation ratios than those
that can be attained in EAE work, but were nevertheless
convincing in demonstrating that the initial immune reac-
tion certainly waned as disease progressed.
This is indeed the converse of what was described as
“original antigenic sin” (15, 16). In this doctrine, the im-
mune response to a subsequent exposure to a new strain of
influenza virus boosts the response to the original strain of
immunizing antigen. This doctrine pertains to both anti-
body and cytotoxic T cell responses to viral antigens (17,
18). It is raised as a major problem for vaccine manufactur-
ers who would like to immunize against viral variants (19).
This is a major challenge on a yearly basis for influenza vac-
cines, and a dramatic challenge in developing a vaccine to
HIV, which is so variable. But examination of this doctrine
reveals that quite the opposite seems to occur in auto-
immunity. The immune response to the initiating self-anti-
gen in autoimmunity disappears, as disease enters the stage
where clinical progression and then chronicity prevail.
If intramolecular and intermolecular epitope spreading
are characteristic of the immune response in autoimmune
disease, would this negate the possibility of antigen-specific
immune therapy? Fortunately, data from Tuohy and col-
leagues (20), and others (21, 22), indicate that certain dom-
inant immune responses prevail in chronic autoimmunity,
and that control of these responses can culminate in ame- 
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lioration of ongoing disease (14, 21–23). For instance, at
autopsy in MS brain, T and B cells reactive to an epitope
on MBP, p87–99, can be detected (3, 4). Three years ago,
in the pages of this journal, Tuohy and colleagues revealed
that they could block relapses of EAE, after disease was initially
induced with PLPp139–151, by administering MBPp87–99
(20). They induced EAE by immunizing mice with PLP. The
immune response spread intramolecularly to other PLP
epitopes, and then intermolecularly to other myelin anti-
gens, including MBP. Epitope spreading was manifest clin-
ically as relapsing paralysis. One of the antigens targeted by
the immune response after intermolecular epitope spread-
ing was MBPp87–99. Administration of this MBP frag-
ment suppressed further episodes of paralysis. This trans-
acting suppression is mediated by cytokines such as IL-4
(14, 22), which are released after T cells encounter low af-
finity MBP peptides or altered peptide ligands (APLs; refer-
ence 14). These results implied that if one can suppress an
immune response to a critical immunogenic epitope that
can be detected during chronic disease, it may be possible
to intervene and treat autoimmunity, despite the possibility
that an alternate antigen or microbial mimic may have ini-
tially triggered the disease. An APL of MBPp87–99 is now
in phase II trials of MS, based on the finding that a major T
and B cell response is detectable in an MS brain at autopsy.
Indeed, antibodies to MBPp87–99 can be seen in MS at
the site of disease, where vesiculated myelin is demonstra-
ble by electron microscopy (23).
There are stark differences between immunity to viral
antigens, where “original antigenic sin” provides a reason-
able explanation for the persistence of responses to the first
encounter with virus, and autoimmunity to self-antigens,
where the initial immune response wanes over time. It is
also important to recognize some essential differences be-
tween autoimmunity and immunity to microbes. In au-
toimmunity, the antigen persists, although ancillary signals
surrounding the self-constituent, such as cytokines, costim-
ulatory molecules, and MHC, may be varied over time,
thus changing the “antigenicity” of self. In immunity to
microbes, the pathogen is either removed by the immune
reaction or immunity is subverted, resulting in persistence
of the microbe if the host survives. Elaborate microbial es-
cape mechanisms include mutation of microbial genes and
variations in microbial antigenicity, as well as the produc-
tion of mediators, with the properties of cytokines and
chemokines, that suppress immune attack. Often persis-
tence involves microbial genes turning off critical genes in
the host. Thus, original antigenic sin may describe how
certain initial immune responses to microbes remain domi-
nant over time. However, in autoimmunity, the response
to the inciting antigen fades, whereas in microbial immu-
nity the initial response may dominate.
There are some situations where microbial immunity
and autoimmunity do share some similarities, and the con-
cept of original antigenic sin is violated, even for viral im-
munity. Using MHC class I tetramers complexed with a
peptide from lymphocytic choriomeningitis virus (LCMV),
Gallimore et al. demonstrated that the fate of CD8
 
1
 
 virus-
specific T cells is determined in part by antigen load (24). Af-
ter exposure to high doses of virus, these anti-LCMV CD8
 
1
 
T cells were present in the spleen during acute infection, but
disappeared 2 mo later. These cells may have died from IL
Figure 1. Mechanism for intramolecular
and intermolecular epitope spreading in au-
toimmunity. After the initial encounter
with a virus mimicking an epitope on a my-
elin protein, immunity to various myelin
components arises. First responses often may
be directed to a PLP peptide like PLPp210–
244 during the initial phase of the disease.
As the disease recurs or progresses, the T
cell responses spread to other determinants
(indicated by the letter D) on PLP, such as
PLP peptide p50–59, protein 1 D2. As in-
tramolecular spreading occurs, the residual
response to protein 1 determinant 1 wanes
and becomes undetectable. The immune
response spreads to other determinants on
other proteins, a process called intermolecu-
lar epitope spreading. T cells can be de-
tected that are reactive to MBP, protein 2
determinants 3 and 4, or MOG, protein 3
determinants 5 and 6. One can suppress the
spreading response by giving a soluble frag-
ment of a protein that elicits Th2 T cell re-
sponses, involving cytokines like IL-4,
which subverts spreading (see APLs). The
yellow arrows indicate that IL-4 is turning
each Th response from a Th1 to a Th2 response (lower bars). Although the decreasing heights of the bars indicate that the sequential Th1 responses are
reduced, they may be increased upon stimulation during relapses of disease. The yellow thunderbolt indicates that the initiating autoimmune response
wanes, and may be undetectable as the disease progresses. In this way an entire inflammatory infiltrate can be cleared using one suppressive peptide frag-
ment (22). The red cones on the right indicate the size of an inflammatory infiltrate, comprised largely of bystander T cells, at the site of disease. Treat-
ment with APLs can reduce the size of these inflammatory infiltrates (22). 
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starvation or activation-induced apoptosis. The characteris-
tics of the autoimmune response more closely resemble stim-
ulation with high doses of virus, which may resemble the
persistent and sometimes “high dose” of a self-antigen. One
of the problems in directly comparing these studies in micro-
bial immunity with work on autoimmunity is that most
assays in microbial systems focus on CD8
 
1
 
-mediated cyto-
toxicity, whereas most research on autoimmunity involves
analysis of proliferation responses in CD4
 
1
 
 T cells.
Understanding of these differences between autoimmu-
nity and microbial immunity is further complicated by the
imaginary boundary between the world of self and the
world of microbes. For example, MBPp87–99, a dominant
target of the T and B cell response in MS brain, is com-
prised of a motif with the peptide HFFK. This motif con-
tains the major TCR contact lysine (2), which is also the
main antibody contact (4), and the major MHC anchor in
the neighboring residue, phenylalanine (2). The peptide se-
quence HFFK is common to a large number of microbial
antigens (4), including many subtypes of human papilloma
virus and other viral antigens. Some of these peptide se-
quences from microbes can either trigger ongoing demyeli-
nating disease (25), or protect from paralytic disease (26).
Thus, it is very puzzling how the immune system can dis-
criminate between an epitope containing HFFK, which
could be derived from either a microbe or a self-constitu-
ent. Solution of this enigma might help explain the basis of
self-/non-self-recognition. At present, the explanation of
the persistence and dominance of the initial immune re-
sponse to a virus can be explained with the concept of orig-
inal antigenic sin. Yet, it is now clear that the very opposite
of original antigenic sin ensues as autoimmunity develops.
What may confound immunization to viruses may be a po-
tential blessing in the design of immune therapies to counter
epitope spreading in autoimmune disease.
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